Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

NNRTI hypersusceptibility.

Jamael Delgado¹, Nancy Shulman

¹University of North Dakota School of Medicine & Health Sciences, Grand Forks, North Dakota, USA.

The AIDS Reader

|February 3, 2005

Summary

Certain HIV strains show hypersusceptibility to nonnucleoside reverse transcriptase inhibitors (NNRTIs), leading to better treatment outcomes. This phenomenon, linked to specific mutations, may influence future HIV resistance evolution.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.

The Journal of infectious diseases·2017

Same author

Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.

Clinical drug investigation·2017

Same author

Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing.

PloS one·2014

Same author

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.

European journal of clinical pharmacology·2013

Same author

Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients.

Retrovirology·2008

Same author

Case files from Stanford University Medical Center: ten years of HAART: a long wait for full HIV suppression.

MedGenMed : Medscape general medicine·2007

Area of Science:

Virology
HIV Research
Drug Resistance

Background:

Hypersusceptibility to nonnucleoside reverse transcriptase inhibitors (NNRTIs) is observed in approximately 30% of HIV isolates resistant to nucleoside reverse transcriptase inhibitors.
This increased susceptibility to NNRTIs compared to wild-type HIV has been linked to improved virologic outcomes in clinical settings.

Purpose of the Study:

To investigate the phenomenon of HIV hypersusceptibility to NNRTIs.
To explore the association between specific mutations and efavirenz hypersusceptibility.
To understand the potential impact of hypersusceptibility on HIV treatment strategies and resistance evolution.

Main Methods:

Phenotypic susceptibility testing of HIV isolates.
Analysis of clinical trial and observational cohort data.
Identification of specific mutations associated with hypersusceptibility (e.g., at positions 215, 208, 118).

Main Results:

Approximately 30% of HIV isolates with nucleoside reverse transcriptase inhibitor resistance exhibit hypersusceptibility to NNRTIs.
Specific nucleoside mutations (positions 215, 208, 118) are associated with efavirenz hypersusceptibility.
No biochemical or structural studies have yet explained the mechanism of this hypersusceptibility on NNRTI binding.

Conclusions:

HIV hypersusceptibility to NNRTIs is a documented phenomenon associated with better clinical outcomes.
While specific mutations are linked to this hypersusceptibility, the underlying biochemical mechanisms require further investigation.
Currently, hypersusceptibility cannot guide HIV therapy, but it may impact the development of antiretroviral resistance in treatment-naive patients.

Related Experiment Videos